Drugs / FRTX-02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05382819 | May 2022 → Feb 2023 | atopic eczema | Fresh Tracks Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FRTX-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05382819 ↗ |
| Action | Inhibit | “FRTX-02 is an orally-available, potent and selective DYRK1A inhibitor.” NCT05382819 ↗ |
| Route | Oral | “FRTX-02 is an orally-available, potent and selective DYRK1A inhibitor.” NCT05382819 ↗ |
| Target | DYRK1A | “FRTX-02 is an orally-available, potent and selective DYRK1A inhibitor.” NCT05382819 ↗ |